文献速递焦虑、强迫与应激相关障碍

书面暴露疗法与延长暴露疗法治疗创伤后应激障碍的随机临床试验

Written Exposure Therapy vs Prolonged Exposure Therapy in the Treatment of Posttraumatic Stress Disorder: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2023-01-01

该随机非劣效性试验纳入178名退伍军人PTSD患者,比较书面暴露疗法(WET)与延长暴露疗法(PE)。结果显示WET在PTSD症状改善上非劣效于PE,且脱落率显著更低(12.5% vs 35.6%),提示WET可能克服PTSD治疗障碍。

要点

  • WET在PTSD症状改善上非劣效于PE,最大差异在第10周利于WET。
  • WET脱落率显著低于PE(12.5% vs 35.6%)。
  • WET为简短疗法,可能降低患者和临床医生的治疗障碍。

核心结论

  • 在退伍军人PTSD患者中,WET在PTSD症状变化上非劣效于PE,且与显著更低的脱落率相关。

研究设计与样本

  • 随机非劣效性临床试验,于2019年9月9日至2022年4月30日在3个退伍军人事务医疗中心进行,纳入178名PTSD退伍军人。

主要发现

  • 从基线到所有后续评估,WET组PTSD症状严重程度变化非劣效于PE组。
  • 治疗间最大差异出现在第10周,利于WET(平均差异2.42分[95%CI, 0.35-1.46])。
  • WET组脱落率显著低于PE组(11[12.5%] vs 32[35.6%];χ2=12.91;Cramer V=0.27)。

关键数值与推荐

  • 非劣效性定义为两组间CAPS-5评分差异小于10分。
  • WET组接受5至7次45-60分钟会话,PE组接受8至15次90分钟会话。

临床怎么用

  • WET可作为PTSD的简短有效治疗选择,尤其适合希望减少脱落的情况。
  • 临床决策时可考虑WET作为PE的替代方案,以降低治疗负担和脱落风险。

局限性

  • 研究仅纳入退伍军人,结果外推至其他人群需谨慎。
  • 样本以男性为主(75.3%),可能限制性别差异的推断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Evidence-based treatments for posttraumatic stress disorder (PTSD) exist, but all require 8 to 15 sessions and thus are less likely to be completed than brief treatments. Written exposure therapy (WET) is a brief and efficacious treatment that has not been directly compared with prolonged exposure therapy (PE), a more time-intensive, exposure-based treatment. OBJECTIVE: To determine whether WET is noninferior to PE in treating PTSD among veterans. DESIGN, SETTING, AND PARTICIPANTS: A randomized noninferiority clinical trial was conducted between September 9, 2019, and April 30, 2022. Participants were 178 veterans with PTSD presenting to 1 of 3 Veterans Affairs medical centers. Inclusion criteria consisted of a primary diagnosis of PTSD and stable medication. Exclusion criteria included current psychotherapy for PTSD, high suicide risk, active psychosis, unstable bipolar disorder, and severe cognitive impairment. Independent evaluations were conducted at baseline and 10, 20, and 30 weeks after the first treatment session. Data were analyzed from January 1 to March 31, 2023. INTERVENTIONS: Participants assigned to WET (n = 88) received five to seven 45- to 60-minute sessions. Participants assigned to PE (n = 90) received eight to fifteen 90-minute sessions. The WET sessions included 30 minutes of writing-based imaginal exposure conducted in session, whereas PE sessions included 40 minutes of in-session imaginal exposure and between-session in vivo exposures. MAIN OUTCOMES AND MEASURES: The primary outcome was change in PTSD symptom severity measured with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) from baseline to the 20-week assessment; noninferiority was defined as a less than 10-point difference between the 2 treatment groups. Difference in treatment dropout was also examined. RESULTS: Of the 178 participants, 134 (75.3%) were men, and the mean (SD) age was 44.97 (13.66) years. In terms of race, 37 participants (20.8%) were Black, 112 (62.9%) were White, 11 (6.2%) were more than 1 race, and 18 (10.1%) were of other race (including American Indian or Alaska Native, Asian, and Native Hawaiian or Other Pacific Islander [some participants did not specify their race when selecting the category "other"]); in terms of ethnicity, 19 participants (10.7%) were Hispanic. Changes in PTSD symptom severity from baseline to all subsequent assessments among individuals randomized to WET were noninferior relative to individuals randomized to PE. The largest difference between treatments was observed at 10 weeks and was in favor of WET (mean difference, 2.42 [95% CI, 0.35-1.46] points). Participants were significantly less likely to drop out of WET compared with PE (11 [12.5%] vs 32 [35.6%]; χ2 = 12.91; Cramer V = 0.27). CONCLUSIONS AND RELEVANCE: In this study, WET was noninferior to PE in PTSD symptom change and was associated with significantly less attrition. Findings suggest that WET may transcend previously observed barriers to PTSD treatment for both patients and clinicians. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03962504.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Sloan DM, Marx BP, Acierno R, et al. Written Exposure Therapy vs Prolonged Exposure Therapy in the Treatment of Posttraumatic Stress Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2023. PMID: 37610727. doi:10.1001/jamapsychiatry.2023.2810

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。